NovoCure (NVCR) shares soared 5.3% in the last trading session to close at $18. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.9% loss over the past four weeks.The sudden rise in the stock price can be attributed to the growing investors optimism related to the company’s efforts in the development and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, which are approved for the ...

NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. NovoCure (NVCR 7.34%), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street's estimate of $146 million. The first quarter was marked by considerable revenue growth for NovoCure. GAAP revenue reached $155 ...